Key points are not available for this paper at this time.
ObjectiveThis prospective study evaluated the therapeutic efficacy of Diosgenin in mitigating Oxazolone-induced ulcerative colitis in male BALB/c mice.MethodMice aged 10-11 weeks were randomized into five groups and subjected to a nine-day protocol involving skin sensitization and intra-rectal Oxazolone challenge. Diosgenin was administered orally at 3 mg/kg and 30 mg/kg twice daily, with Tofacitinib at 60 mg/kg as a reference control. Disease severity was assessed via clinical activity scores, which include tested parameters.ResultsOxazolone-induced acute colitis was characterized by significant weight loss, increased diarrhoea scores, and an >8-fold increase in rectal bleeding scores compared with vehicle-treated mice, confirming successful disease induction (p 90% in the Tofacitinib 60 mg/kg group.ConclusionThese findings suggest Diosgenin offers substantial protection against Oxazolone-induced colitis via cytokine modulation and pSTAT3 inhibition, highlighting its potential as a natural anti-inflammatory agent for colitis management.
Narayan et al. (Wed,) studied this question.